<ul>
	<li><strong>Serious Infections</strong>: Avoid use of Upadacitinib in patients with active, serious infection, including localized infections.</li>
	<li><strong>Malignancy</strong>: Consider the risks and benefits of Upadacitinib treatment prior to initiating therapy in patients with a known malignancy.</li>
	<li><strong>Thrombosis</strong>: Consider the risks and benefits prior to treating patients who may be at increased risk of thrombosis. Promptly evaluate patients with symptoms of thrombosis and treat appropriately.</li>
	<li><strong>Gastrointestinal Perforations</strong>: Use with caution in patients who may be at increased risk.</li>
	<li>Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.</li>
	<li><strong>Embryo-Fetal Toxicity</strong>: Upadacitinib may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.</li>
	<li>Vaccinations: Avoid use of Upadacitinib with live vaccines.</li>
</ul>